[HTML][HTML] Severe asthma phenotypes in patients controlled with omalizumab: a real-world study

P Campo, GS Campos, MB Aparicio, AM Jorge… - Respiratory …, 2019 - Elsevier
… These, and the phenotypes suggested by the Spanish Society … After more than a decade of
clinical experience with omalizumabapproaches identified at least 3–5 phenotypes of severe

Cost-effectiveness analysis of omalizumab for the treatment of severe persistent asthma in real clinical practice in Spain

MC Vennera, A Valero, E Uría, C Forné… - Clinical drug …, 2016 - Springer
… effectiveness of omalizumab compared with standard treatment for the control of … Omalizumab
therapy in severe asthma: experience from the Spanish registrysome new approaches

Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness

C Pelaia, C Calabrese, R Terracciano… - Therapeutic …, 2018 - journals.sagepub.com
experienced a relapse of asthma exacerbations during the first 5 months after forced withdrawal
of omalizumab treatmentapproach, when prescribing an add-on biological treatment for …

[HTML][HTML] Effectiveness and pharmacoeconomic analysis of the treatment of severe asthma with omalizumab in clinical practice

E Martínez-Moragón, M Climent, E Chiner… - Farmacia …, 2019 - Elsevier
asthmatic population, these patients experience the … (Spain). The objective of the study
was to assess the effectiveness of omalizumab for the treatment of patients with severe asthma, …

[HTML][HTML] Economic impact and clinical outcomes of omalizumab add-on therapy for patients with severe persistent asthma: a real-world study

LM Entrenas Costa, F Casas-Maldonado… - PharmacoEconomics …, 2019 - Springer
… carried out in patients with severe asthma treated with omalizumab in daily practice …
Omalizumab therapy in severe asthma: experience from the Spanish registrysome new approaches

[HTML][HTML] Efficacy and safety of reslizumab in patients with severe asthma with inadequate response to omalizumab: a multicenter, open-label pilot study

LAP de Llano, BG Cosío, C Domingo, I Urrutia… - The Journal of Allergy …, 2019 - Elsevier
Methods … -experienced and omalizumab-naive patients, pointing toward an improvement in
… In Spain, the Spanish Severe Asthma Registry found a dropout rate of 18.7%: 10.5% due to …

Asthma control in patients with severe eosinophilic asthma treated with reslizumab: Spanish real-life data

…, Reslizumab Real-Life Spanish Group - Journal of Asthma …, 2022 - Taylor & Francis
… data from The International Severe Asthma Registry (ISAR) … experienced a significant
reduction in the number of severe … with severe eosinophilic asthma and a history of omalizumab

Efficacy and effectiveness of omalizumab in the treatment of childhood asthma

M Tortajada-Girbés, R Bousquet… - Expert review of …, 2018 - Taylor & Francis
severe asthma in asthmatic children aged 6–14 years attending pneumology and allergy units
in Spain … [Citation31] (le: 1 ++) and proposes a new approach to reduce autumnal asthma

A review of omalizumab for the management of severe asthma

CH Lin, SL Cheng - Drug design, development and therapy, 2016 - Taylor & Francis
… Citation11 BT is a novel invasive approach developed to … ’s experience with omalizumab,
we support that it is an optimal … in a Spanish multicenter registry study, where nonallergic …

FENOMA study: Achieving full control in patients with severe allergic asthma

S Cabrejos, A Moreira, A Ramirez… - Journal of Asthma …, 2020 - Taylor & Francis
… of clinically significant and severe asthma exacerbations and … in Spain in 345 adult patients
with severe persistent asthma … of OCS after 12 months of omalizumab therapy, and reported …